Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: Results of three studies

H. Szwed, J. Hradec, I. Préda

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Several clinical studies have compared the anti-ischaemic properties of trimetazidine used as monotherapy with those of standard anti-anginal therapy. In the treatment of uncontrolled angina pectoris, the addition of a metabolic agent such as trimetazidine to existing therapy with a haemodynamic agent would appear to confer advantages over the addition of a second haemodynamic agent. Here we report the results of three studies conducted in Poland, the Czech Republic and Hungary that provide additional evidence for the beneficial effects of combining trimetazidine with a conventional haemodynamic agent such as β-blockers, long-acting nitrate or calcium channel blockers. This combination provided significant benefits in terms of improved exercise capacity and decreased number of angina attacks along with a good tolerability profile.

Original languageEnglish
Pages (from-to)S25-S28
JournalCoronary Artery Disease
Volume12
Issue numberSUPPL. 1
Publication statusPublished - Apr 2 2001

Keywords

  • Angina pectoris
  • Coronary artery disease
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: Results of three studies'. Together they form a unique fingerprint.

  • Cite this